Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma

Pancreas

Volumn 38, Issue 4, 2009, Pages 422-426

  Liao, Wei Chih ^a,b   Wu, Ming Shiang ^a   Wang, Hsiu Po ^a   Tien, Yu Wen ^a   Lin, Jaw Town ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

Chronic pancreatitis; Heat shock protein 27; Pancreatic adenocarcinoma; Receiver operating characteristic curve; Sensitivity and specificity

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; HEAT SHOCK PROTEIN 27; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; BLOOD; MIDDLE AGED; PANCREAS TUMOR; PREDICTION AND FORECASTING;

ADULT; AGED; CA-19-9 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 66149096267     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318198281d     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
4. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363: 1049-1057.
5. Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas. 2008;36:e15-e20.
6. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer. 1996;78:57-62. (Pubitemid 26189905)
7. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-138.
8. Lin M, Broadberry RE. Immunohematology in Taiwan. Transfus Med Rev. 1998;12:56-72.
9. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503. (Pubitemid 17152971)
10. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.
11. Satake K, Takeuchi T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas. 1994;9: 720-724. (Pubitemid 24317823)
12. Maire F, Micard S, Hammel P, et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer. 2002;87:551-554. (Pubitemid 35052728)
13. Chang CY, Huang SP, Chiu HM, et al. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology. 2006;53:1-4.
14. Tumour markers in gastrointestinal cancers: EGTM recommendations. European Group on Tumour Markers. Anticancer Res. 1999;19: 2811-2815.
15. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464-1484.
16. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer. 1988;62:2287-2290.
17. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23:4524-4531. (Pubitemid 46196582)
18. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442-446. (Pubitemid 43166133)
19. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005;65: 11083-11093. (Pubitemid 41713379)
20. Rane MJ, Pan Y, Singh S, et al. Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem. 2003;278:27828-27835. (Pubitemid 36899975)
21. Charette SJ, Lavoie JN, Lambert H, et al. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol Cell Biol. 2000;20: 7602-7612. (Pubitemid 30736884)
22. Tashiro M, Schafer C, Yao H, et al. Arginine induced acute pancreatitis alters the actin cytoskeleton and increases heat shock protein expression in rat pancreatic acinar cells. Gut. 2001;49:241-250. (Pubitemid 32675119)
23. Ethridge RT, Ehlers RA, Hellmich MR, et al. Acute pancreatitis results in induction of heat shock proteins 70 and 27 and heat shock factor-1. Pancreas. 2000;21:248-256. (Pubitemid 30749100)
24. Parcellier A, Schmitt E, Brunet M, et al. Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal. 2005;7:404-413. (Pubitemid 40279808)
25. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006; 5:2592-2601. (Pubitemid 44785803)
26. Lanneau D, Brunet M, Frisan E, et al. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med. 2008.
27. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 2007;31:1345-1350.
28. Melle C, Ernst G, Escher N, et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem. 2007;53:629-635. (Pubitemid 46580232)
29. Gönen M. Comparison and covariate adjustment of ROC curves. In: Gönen M, ed. Analyzing Receiver Operating Characteristic Curves with SAS. Cary, NC: SAS Institute Inc, 2007:37-52.
30. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433-1437.
31. Talamini G, Falconi M, Bassi C, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol. 1999;94:1253-1260. (Pubitemid 29214638)
32. Maisonneuve P, Lowenfels AB. Chronic pancreatitis and pancreatic cancer. Dig Dis. 2002;20:32-37.
33. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995;109:247-251.
34. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9-14. (Pubitemid 38490509)
35. Franco L, Doria D, Bertazzoni E, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat. 2004;73:51-58. (Pubitemid 38446471)
36. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161:89421-89428
37. Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 2000;20:935-946.
38. Liptay S, Weber CK, Ludwig L, et al. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 2003;105:735-746. (Pubitemid 36706095)
39. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
40. Schlosser W, Schlosser S, Ramadani M, et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas. 2002;25:26-30.
41. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990. (Pubitemid 29135954)
42. Garcea G, Dennison AR, Steward WP, et al. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 2005;5:514-529. (Pubitemid 41407282)
43. Alford KA, Glennie S, Turrell BR, et al. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-betaYactivated kinase-1 (TAK1)Ymediated signaling. J Biol Chem. 2007;282:6232-6241. (Pubitemid 47100877)
44. Lasa M, Mahtani KR, Finch A, et al. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol. 2000;20:4265-4274. (Pubitemid 30346621)
45. De AK, Roach SE. Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. J Immunoassay Immunochem. 2004;25:159-170.
46. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene. 2000;19:4855-4863. (Pubitemid 30809022)
47. Kubisch C, Dimagno MJ, Tietz AB, et al. Overexpression of heat shock protein Hsp27 protects against cerulein-induced pancreatitis. Gastroenterology. 2004;127:275-286. (Pubitemid 38962294)
48. Leja-Szpak A, Jaworek J, Szklarczyk J, et al. Melatonin stimulates HSP27 phosphorylation in human pancreatic carcinoma cells (PANC-1). J Physiol Pharmacol. 2007;58(suppl 3):177-188. (Pubitemid 47523114)